[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588481":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"iTBS","ACTIVE_COMPARATOR","Patients are treated with intermittent theta burst stimulation (iTBS).",[13],"Device: intermittent theta burst stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"sham-iTBS","SHAM_COMPARATOR","Patients are treated with sham intermittent theta burst stimulation (sham-iTBS).",[19],"Device: sham intermittent theta burst stimulation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","intermittent theta burst stimulation","The iTBS delivered to the ipsilesional primary motor cortex (M1) at 80% resting motor threshold (RMT). Each session consists of 600 pulses (3-minute trains of 50 Hz triplets repeated every 10 seconds, twice daily with a 5-minute interval), administered for 7 consecutive days starting within 6 hours post-randomization.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"sham intermittent theta burst stimulation","Sham-iTBS is performed in the same way as the treatment group but uses 20% RMT.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Yi Yang, MD, PhD","CONTACT","0086-13756661217","doctor_yangyi@163.com",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Changchun","Jilin","130000","China","CN",{"type":46,"coordinates":47},"Point",[48,49],125.32278,43.88,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Yi Yang","Vice President of First Hospital of Jilin University","100588481","itbs-for-acute-ischemic-stroke-after-thrombectomy-100588481",false,"NCT06941961","iTBS for Acute Ischemic Stroke After Thrombectomy","Efficacy and Safety of Intermittent Theta Burst Stimulation in Acute Anterior Circulation Ischemic Stroke Patients Undergoing Mechanical Thrombectomy","Inclusion Criteria:\n\n* 1\\) Age 18-85 years, regardless of gender.\n* 2\\) Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA.\n* 3\\) Mechanical thrombectomy (MT) performed within 24 hours of symptom onset.\n* 4\\) Successful Reperfusion: Post-MT eTICI score ≥ 2b.\n* 5\\) NIHSS score 5-25 at 24 hours post-MT, with ≥2 points in at least one limb.\n\nExclusion Criteria:\n\n* 1\\) Pre-stroke modified Rankin Scale (mRS) score ≥2.\n* 2\\) PH2-type intracranial hemorrhage on brain CT post-MT.\n* 3\\) Patients who underwent intracranial stent placement during MT.\n* 4\\) Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic\u002Fmagnetic-sensitive devices.\n* 5\\) Severe consciousness impairment, cognitive dysfunction, or psychiatric disorders preventing compliance with iTBS.\n* 6\\) Expected survival \\\u003C3 months due to other medical conditions or inability to complete follow-up for any reason.\n* 7\\) Participation in another interventional study.\n* 8\\) Any other condition deemed unsuitable for enrollment by the investigator.","ALL","18 Years","85 Years",{"count":68,"type":69},178,"ESTIMATED","INTERVENTIONAL",[72],"NA","The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.",[75],"Ischemic Stroke","2025-04-28",{"date":78,"type":79},"2025-04-30","ACTUAL",{"date":81,"type":79},"2025-04-25",{"date":83,"type":69},"2026-08-01",{"name":55,"class":6},1]